LDE225 and INC424 in Combination in myelofibrosis patients.

• Research type

  Research Study

• Full title

  A Phase 1b/II, open-label, multi-center, dose-finding study to assess safety and efficacy of the oral combination of LDE225 and INC424 (Ruxolitinib) in patients with myelofibrosis.

• IRAS ID

  125532

• Contact name

  Claire Harrison

• Contact email

  claire.harrison@gstt.nhs.uk

• Sponsor organisation

  Novartis Pharmaceuticals UK Ltd.

• Eudract number

  2012-004023-20

• ISRCTN Number

  n.a

• Clinicaltrials.gov Identifier

  n.a

• REC name

  East of England - Cambridge South Research Ethics Committee

• REC reference

  13/EE/0117

• Date of REC Opinion

  5 Jul 2013

• REC opinion

  Further Information Favourable Opinion